Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    DSSTox_CID_3078

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Caplin Steriles Gets USFDA Nod for Generic Foscarnet Sodium
    Caplin Steriles Gets USFDA Nod for Generic Foscarnet Sodium

    18 May 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/caplin-steriles-receives-usfda-approval-for-generic-foscarnet-sodium-injection-20224

    INDPHARMAPOST
    18 May 2026
    Share Share
    Enforcement Report - Week of October 25, 2023
    Enforcement Report - Week of October 25, 2023

    25 Oct 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf

    FDA
    25 Oct 2023
    Share Share
    Avet's Generic Foscarnet Sodium Receives Approval in the U.S.
    Avet's Generic Foscarnet Sodium Receives Approval in the U.S.

    05 Jun 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213807

    FDA
    05 Jun 2023
    Share Share
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older
    Takeda’s LIVTENCITY Available for Certain Individuals Ages 12 Years and Older

    02 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211202005653/en

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more
    Takeda’s LIVTENCITYTM Approved by FDA in CMV; & more

    23 Nov 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211123006185/en

    BUSINESSWIRE
    23 Nov 2021
    Share Share
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus
    FDA's ADAC unanimously backs Takeda's drug for post-transplant cytomegalovirus

    08 Oct 2021

    // Z. Brennan ENDPTS

    https://endpts.com/fdas-antimicrobial-adcomm-unanimously-backs-takedas-drug-for-post-transplant-cytomegalovirus/

    Z. Brennan ENDPTS
    08 Oct 2021
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.